Mineralys Therapeutics, Inc. MLYS Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s deferred tax assets, valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s deferred tax assets, valuation allowance?
- Mineralys Therapeutics, Inc. (MLYS) reported deferred tax assets, valuation allowance of $121.25M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s deferred tax assets, valuation allowance?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s deferred tax assets, valuation allowance has grown at a 111.0% compound annual growth rate (CAGR), from $12.92M to $121.25M.